Navigation Links
Response to preoperative therapy may predict survival in pancreatic cancer patients
Date:5/28/2010

CHICAGO, IL. (May 28, 2010)Cancer of the pancreasa glandular organ that lies behind the stomach and secretes vital enzymes and hormonesseldom is detected in early stages, making treatment difficult and survival statistics particularly grim. However, new research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least.

The research, led by Yun Shin Chun, M.D., a surgical oncologist at Fox Chase, will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 6.

Since the 1980s, Fox Chase has been committed to finding better treatments for this intractable disease. In 1986, the Center conducted the first trial in pancreatic cancer of "multimodal" preoperative therapy (the use of more than one kind of treatment, such as chemotherapy and radiation, to kill tumor cells before surgery), and a phase I trial of gemcitabine in the 1990s established the safe dosage for the chemotherapy drug, now widely used in treating the disease.

In the current study, Chun and colleagues wanted to know whether response to preoperative therapy predicts survival in pancreatic adenocarcinomathe most common type of pancreatic cancer. "For many cancersbreast, esophagus, stomach, and colorectal liver metastasesit has been shown that survival is much better in people who have a good pathologic response to preoperative therapymeaning that many tumor cells are killedthan in people who do not have a good pathologic response," says Chun. "But this has not been established in pancreatic cancer; previous studies have shown conflicting results."

In hopes of clearing up the confusion, Chun and colleagues reviewed data on 135 patients who had preoperative therapy and surgery. Fox Chase pathologist Harry Cooper, M.D., examined slides of the patients' tumors and classified their response to preoperative treatment as minor, partial, or major, based on the amount of fibrosis (scarring) in tumor tissue. For patients whose tumors showed major response to preoperative therapy, the median survival was more than five years, compared to seventeen months for those who showed minor response.

Although major response is relatively rareonly 19 percent of patients in the study were so classifiedthe findings give researchers and clinicians important information to build upon. "Going forward, if we can identify molecular factors in tumors associated with a major pathologic response, then we can make important progress in this disease," says Dr. Chun.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Mount Sinai discovers bone marrow plays critical role in enhancing immune response to viruses
2. New Laser Treatment Offers Revolutionary Response to Aesthetic Procedure Candidates' Number One Concern: Recovery Time
3. Unique Marketing Approach to the Energy Drink Market Brings Explosive Response
4. Response to vaccines could depend on your sex
5. Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies
6. Babies Responses to Prenatal Stress Differ by Gender
7. A stress-response system in the ear protects against hearing loss
8. Patients whole genome reveals risk of diseases and adverse drug responses
9. Merely seeing disease symptoms may promote aggressive immune response
10. Protein in Breast Tumors May Predict Chemo Response
11. Bodys Response to Foods Smell, Taste Could Be Diabetes Risk Factor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... ... Month and the focus is on prostate cancer. Second only to skin cancer, prostate ... common cause of cancer related death today; lung cancer remains in the number one spot. ... during his lifetime. Those at highest risk are men who have a family ...
(Date:6/24/2017)... ... ... Doorknobs are for convenience, deadbolts are for security. , There are many ... an alarm system installed. But unless there is a working deadbolt lock that is ... Premier Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders use ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and antioxidants derived ... loss in these patients. , But how often do ophthalmologists and optometrists in Sweden ... at risk of or with early symptoms of AMD? A study published recently ...
(Date:6/23/2017)... ... ... Goodcents Deli Fresh Subs today announced the opening of a new restaurant ... Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by long-time ... in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such a ...
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent ... is MD Now’s 28th facility overall and marks the urgent care center's eighth location ... mile North of The Falls shopping mall. The new clinic offers a wide array ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... -- Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), ... selection of stem cells, today provided a corporate update ... March 31 st , 2017. "We ... quarter of 2017," said Dr. Shai Yarkoni, Chief Executive ... of the first blood cancer patient in the recently ...
Breaking Medicine Technology: